Evidence map›Paper›PMID 25608681›Full record

ArticleAnnals of gastroenterology

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.

Evangelos Cholongitas, George V Papatheodoridis, John Goulis, John Vlachogiannakos, Stylianos Karatapanis, John Ketikoglou, Themistoklis Vasiliadis, George Kontos, Anastasios Karlaftis, Evangelos Akriviadis

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evangelos Cholongitas4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongita, John Goulis, Evangelos Akriviadis), Greece.
George V PapatheodoridisDepartment of Gastroenterology, Athens University Medical School, Laiko General Hospital of Athens (George V. Papatheodoridis, John Vlachogiannakos, Anastasios Karlaftis), Greece.
John Goulis4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongita, John Goulis, Evangelos Akriviadis), Greece.
John VlachogiannakosDepartment of Gastroenterology, Athens University Medical School, Laiko General Hospital of Athens (George V. Papatheodoridis, John Vlachogiannakos, Anastasios Karlaftis), Greece.
Stylianos KaratapanisFirst Department of Internal Medicine, General Hospital of Rhodes (Stylianos Karatapanis), Greece.
John KetikoglouDepartment of Internal Medicine, Hippokration General Hospital of Athens (John Ketikoglou, George Kontos), Greece.
Themistoklis Vasiliadis1st Pr. Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki (Themistoklis Vasiliadis), Greece.
George KontosDepartment of Internal Medicine, Hippokration General Hospital of Athens (John Ketikoglou, George Kontos), Greece.
Anastasios KarlaftisDepartment of Gastroenterology, Athens University Medical School, Laiko General Hospital of Athens (George V. Papatheodoridis, John Vlachogiannakos, Anastasios Karlaftis), Greece.
Evangelos Akriviadis4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongita, John Goulis, Evangelos Akriviadis), Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPatients with HBV-related decompensated cirrhosis (HBV-DeCi) should be treated with potent nucleos(t)ide analogues (NA)[entecavir (ETV) or tenofovir (TDF)]. The aim was the evaluation of safety and efficacy in terms of changes in liver disease course in HBV-DeCi patients treated with ETV or TDF.

methodsIn 52 HBV-DeCi patients clinical and laboratory data, including glomerular filtration rates (GFR), were recorded. The changes in MELD (DMELD) and Child-Pugh (DCTP) scores between baseline and after 6 months of treatment were evaluated. The independent factors associated with survival were evaluated.

results31 patients under TDF and 21 under ETV were evaluated. During a median follow-up of 22.5 months (range: 6-68), there were no differences between the two groups in GFR and serum phosphate levels. At the end of follow up, in the TDF group, 2 patients died and 3 received liver transplantations (LT), while in the ETV group, 1 patient died and 3 received LT. In multivariable Cox regression analysis, DMELD was independently associated with the outcome in the total cohort (HR: 1.78, 95%C.I.:1.12-2.79, P=0.013) as well as in the subgroup of naïve (n=37) patients (HR: 1.8, 95%C.I.:1.19-4.5, P=0.03). Finally, in the non-hepatocellular carcinoma patients, the DCTP score was independently associated with the outcome in the total cohort (HR: 2.64, 95%C.I.: 1.21-7.29, P=0.015).

conclusionsTDF and ETV appear to have similar renal safety profile in HBV-DeCi patients. DMELD score in the total cohort and DCTP score in non-HCC patients were independently associated with the outcome; these findings need confirmation in larger studies.

Indexed as

entecavirKeywords Decompensated cirrhosisnucleos(t)ide analoguestenofovir

Identifiers

PMID25608681
PMCPMC4289983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.